Cumulative Benefit Over 52 Weeks With Deucravacitinib Versus Apremilast in Moderate to Severe Plaque Psoriasis: POETYK PSO-1 Post Hoc Analysis

By sjmartinez • June 23, 2024

Armstrong AW, Park SH, Patel V, Nicolas P, Wang WJ, Colombo MJ, Chirikov V. Cumulative Benefit Over 52 Weeks With Deucravacitinib Versus Apremilast in Moderate to Severe Plaque Psoriasis: POETYK PSO-1 Post Hoc Analysis. Dermatol Ther (Heidelb). 2024 Jun 22. doi: 10.1007/s13555-024-01201-4. Epub ahead of print. PMID: 38907877.

Tags: apremilast, cumulative clinical benefit, Dermatology, deucravacitinib, Oral treatments, psoriasis, Publications, Small molecules

Predatory Conferences and Journals in Dermatology Are Black Widow Parties

Murrell DF, Weinberg JM, Yamauchi PS, Abdelmaksoud A, Grabbe S, Goldust M. Predatory Conferences and Journals in Dermatology Are Black Widow Parties. Skinmed. 2024 Oct[...]

Putative pseudolysogeny-dependent phage gene implicated in the superinfection resistance of Cutibacterium acnes

Wottrich S, Mendonca S, Safarpour C, Nguyen C, Marinelli LJ, Hancock SP, Modlin RL, Parker JM. Putative pseudolysogeny-dependent phage gene implicated in the superinfection resistance[...]

Contact Dermatitis in the United States: A Population-Based Study on Patient Visit Characteristics and Treatment Prescription Patterns

Hao A, Yu RP, Kikuchi R, Sadrolashrafi K, Guo L, Yamamoto RK, Tolson H, Yee D, Bilimoria S, Pourali SP, Adler BL, Armstrong AW. Contact[...]